ArticleProceedings of the National Academy of Sciences of the United States of America1994
Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 240 citations in OpenAlex.
- Role of TRKC and NT-3 proteins in the progression and prognosis of colorectal cancer.Translational cancer research · 2025Article
- Neural Signaling in Cancer.Annual review of neuroscience · 2022Review
- The Neurotrophin Receptor TrkC as a Novel Molecular Target of the Antineuroblastoma Action of Valproic Acid.International journal of molecular sciences · 2021Article
- Hypothalamic Transcriptome Analysis Reveals the Crucial MicroRNAs and mRNAs Affecting Litter Size in Goats.Frontiers in veterinary science · 2021Article
- Neurotrophin Signaling in Medulloblastoma.Cancers · 2020Review
- Review
- Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma.Frontiers in pharmacology · 2019Article
- Expression of nerve growth factor and brain-derived neurotrophic factor in astrocytomas.Oncology letters · 2018Article
- Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017Article
- Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.Medicine · 2017Article
- Neuronal Activity in Ontogeny and Oncology.Trends in cancer · 2017Review
- Metabolic analysis of radioresistant medulloblastoma stem-like clones and potential therapeutic targets.PloS one · 2017Article
- Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker.Oncology letters · 2016Article
- LINC00052 regulates the expression of NTRK3 by miR-128 and miR-485-3p to strengthen HCC cells invasion and migration.Oncotarget · 2016Article
- BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells.Journal of molecular neuroscience : MN · 2016Article
- Neurotrophin signaling in cancer stem cells.Cellular and molecular life sciences : CMLS · 2016Review
- Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.Cancer letters · 2016Article
- Experimental verification of a conserved intronic microRNA located in the human TrkC gene with a cell type-dependent apoptotic function.Cellular and molecular life sciences : CMLS · 2015Article
- TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.Cancer chemotherapy and pharmacology · 2015Article
- Cytogenetic prognostication within medulloblastoma subgroups.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Medulloblastoma, the most common malignant brain tumor of childhood, has a variable prognosis. Although half of the children and young adults with the disease survive longer than 10 years after diagnosis, the others relapse and die despite identical therapy. We have examined the expression of neurotrophins and their receptors in medulloblastoma samples snap frozen in the operating room to preserve RNA integrity. All tumors (n = 12) were found to express mRNA encoding neurotrophin 3 and its receptor TrkC. The level of trkC expression was highly variable, with a more than 50-fold difference between the highest and lowest values. By Kaplan-Meier analysis, patients with tumors expressing high levels of trkC mRNA had significantly longer intervals without disease progression than those with low levels (log-rank, P = 0.03) and a more favorable overall survival (log-rank, P = 0.05). Thus, trkC expression is a prognostic indicator for patients with medulloblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.